Skip to main content

Table 3 GENEDIAB cohort: Plasma EC-SOD, AOPP and Isoprostane concentrations by clinical outcomes during follow-up

From: Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes

  N EC-SOD (ng/ml) N AOPP (μmol/l) N Isoprostane (ng/ml)
Myocardial infarction
Yes 25 194 ± 44 26 60 ± 6 26 2.37 ± 0.24
No 208 196 ± 15 214 66 ± 2 226 1.52 ± 0.08
p   0.51   0.49   0.0003
All-cause mortality
Yes 47 195 ± 30 40 73 ± 6 42 2.22 ± 0.20
No 194 192 ± 14 209 56 ± 4 221 1.71 ± 0.12
p   0.57   0.004   0.002
  1. Results expressed as mean ± SEM. Statistics are ANCOVA adjusted for sex, age, BMI, systolic blood pressure and eGFR (EC-SOD), for sex, age, total cholesterol concentration, and use of ACE inhibitors (AOPP), and for sex, age, diastolic blood pressure, and use of lipid lowering drugs (isoprostane). p < 0.05 is significant.